Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.81 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.54 |
| ▸ | FNTA | P49354 | 3/20 | 0.49 |
| ▸ | FNTB | P49356 | 3/20 | 0.49 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | QPCT | Q16769 | 1/20 | 0.49 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.49 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88059 | 0.90 | CYP19A1 (1.00) | CYP19A1CYP11B1CYP11B2TBXAS1FNTA | |
| Hydrochloric Acid SCHEMBL1507826 | 0.89 | CYP19A1 (0.97) | CYP19A1CYP11B1CYP11B2TBXAS1FNTA | |
| SCHEMBL7841243 | 0.78 | CYP19A1 (0.68) | CYP19A1CYP11B1CYP11B2FNTAFNTB | |
| Benzylimidazole SCHEMBL16236718 | 0.78 | TBXAS1 (0.80) | CYP19A1CYP11B1CYP11B2TBXAS1CYP17A1 | |
| SCHEMBL11387112 | 0.76 | CYP19A1 (0.72) | CYP19A1CYP11B1TBXAS1POLBMAPT | |
| SCHEMBL3737260 | 0.76 | TBXAS1 (0.64) | CYP19A1CYP11B1CYP11B2TBXAS1POLB | |
| SCHEMBL28416685 | 0.76 | CYP19A1 (0.76) | CYP19A1CYP11B1CYP11B2TBXAS1POLB | |
| SCHEMBL15179016 | 0.75 | CYP11B1 (0.76) | CYP19A1CYP11B1CYP11B2TBXAS1CYP17A1 | |
| SCHEMBL30523908 | 0.75 | CYP11B1 (0.76) | CYP19A1CYP11B1CYP11B2TBXAS1CYP17A1 | |
| SCHEMBL30523909 | 0.75 | CYP11B1 (0.76) | CYP19A1CYP11B1CYP11B2TBXAS1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691859-B2 | Prenyl transferase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2010-04-06 | — | — | US | disclosed |
| EP-1382607-B1 | Prenyl transferase inhibitors | IPSEN PHARMA (FR) | 2009-08-19 | — | — | EP | disclosed |
| US-20080176835-A1 | Prenyl Transferase Inhibitors | BIOMEASURE, INCORPORATED | 2008-07-24 | — | — | US | disclosed |
| US-7361656-B2 | Prenyl transferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2008-04-22 | — | — | US | disclosed |
| US-7084135-B1 | Prenyl transferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, SAS (FR) | 2006-08-01 | — | — | US | disclosed |
| US-20060142275-A1 | Prenyl transferase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2006-06-29 | — | — | US | disclosed |
| EP-1140942-B1 | PRENYL TRANSFERASE INHIBITORS | CONSEILS DE RECH SET D APPLIC (FR) | 2004-03-10 | — | — | EP | disclosed |
| EP-1382607-A2 | Prenyl transferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176835-A1 | Prenyl Transferase Inhibitors | FNTA, FNTB, RCE1 | CYP19A1 2162/4885CYP11B1 256/4885CYP11B2 266/4885 |
| US-20060142275-A1 | Prenyl transferase inhibitors | FNTA, FNTB, RCE1 | CYP19A1 2162/4885CYP11B1 256/4885CYP11B2 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.